Trial Profile
A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2020
Price :
$35
*
At a glance
- Drugs ENERGI-F701 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Energenesis Biomedical
- 23 Nov 2020 Status changed from recruiting to completed.
- 02 Sep 2019 Planned End Date changed from 1 Mar 2019 to 3 Feb 2020.
- 02 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 3 Oct 2019.